AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
May 16
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 18, 2025
DataAggregated Company Financials
Companies564
- 7D3.7%
- 3M-10.1%
- 1Y-14.5%
- YTD-7.1%
Regeneron Pharmaceuticals is up 13%, leading the way for the Biotech industry, which has gained 3.7%. During this same period, the Halozyme Therapeutics underperformed, falling 21%. In the past year, the industry is down 14%. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 18 May 2025 | US$895.3b | US$155.9b | -US$24,392,718,921.60 | 16.3x | -36.7x | 5.7x |
| Tue, 15 Apr 2025 | US$740.5b | US$119.2b | -US$36,459,397,381.90 | 19.9x | -20.3x | 6.2x |
| Thu, 13 Mar 2025 | US$834.6b | US$118.7b | -US$37,659,545,163.68 | 18.4x | -22.2x | 7x |
| Sat, 08 Feb 2025 | US$857.1b | US$117.3b | -US$30,948,989,158.04 | 17.2x | -27.7x | 7.3x |
| Mon, 06 Jan 2025 | US$980.2b | US$149.6b | -US$26,354,792,434.12 | 17x | -37.2x | 6.6x |
| Wed, 04 Dec 2024 | US$1.0t | US$149.9b | -US$26,584,927,055.40 | 16.5x | -39.1x | 6.9x |
| Fri, 01 Nov 2024 | US$1.1t | US$147.3b | -US$30,454,139,694.27 | 17.1x | -34.7x | 7.2x |
| Sun, 29 Sep 2024 | US$893.6b | US$113.2b | -US$36,006,680,210.71 | 21.3x | -24.8x | 7.9x |
| Tue, 27 Aug 2024 | US$909.0b | US$113.1b | -US$35,851,266,005.46 | 23.3x | -25.4x | 8x |
| Thu, 25 Jul 2024 | US$1.2t | US$164.5b | -US$28,090,976,401.93 | 28.2x | -43x | 7.3x |
| Sat, 22 Jun 2024 | US$1.1t | US$164.4b | -US$27,943,646,272.00 | 28.1x | -41.1x | 7x |
| Mon, 20 May 2024 | US$1.1t | US$164.6b | -US$26,835,738,666.64 | 23.9x | -42.8x | 7x |
| Wed, 17 Apr 2024 | US$1.1t | US$164.2b | -US$23,402,696,044.05 | 20.5x | -46.3x | 6.6x |
| Fri, 15 Mar 2024 | US$1.2t | US$167.4b | -US$22,100,849,384.54 | 16.3x | -54.1x | 7.1x |
| Sun, 11 Feb 2024 | US$1.2t | US$169.3b | -US$26,263,046,791.87 | 19.8x | -44.2x | 6.9x |
| Tue, 09 Jan 2024 | US$1.4t | US$204.8b | -US$22,499,844,981.00 | 20.8x | -63.1x | 6.9x |
| Thu, 07 Dec 2023 | US$1.3t | US$204.6b | -US$22,056,080,007.00 | 19.4x | -58.1x | 6.3x |
| Sat, 04 Nov 2023 | US$1.2t | US$206.7b | -US$20,531,174,316.00 | 18.8x | -60.4x | 6x |
| Mon, 02 Oct 2023 | US$1.3t | US$207.4b | -US$13,122,605,528.00 | 17.1x | -95.8x | 6.1x |
| Wed, 30 Aug 2023 | US$1.3t | US$207.6b | -US$12,432,896,963.00 | 17.8x | -103.8x | 6.2x |
| Fri, 28 Jul 2023 | US$1.1t | US$186.8b | -US$16,232,166,533.00 | 14.3x | -69.6x | 6x |
| Sun, 25 Jun 2023 | US$1.1t | US$186.2b | -US$16,162,116,001.00 | 13.6x | -70.3x | 6.1x |
| Tue, 23 May 2023 | US$1.2t | US$186.0b | -US$15,902,975,009.00 | 13.3x | -72.9x | 6.2x |
| Thu, 20 Apr 2023 | US$1.2t | US$198.4b | -US$3,264,741,817.00 | 13.6x | -362.5x | 6x |
| Sat, 18 Mar 2023 | US$1.1t | US$199.2b | -US$3,900,694,523.00 | 13.2x | -286.4x | 5.6x |
| Mon, 13 Feb 2023 | US$1.2t | US$202.7b | -US$211,129,546.00 | 16.4x | -5476.8x | 5.7x |
| Wed, 11 Jan 2023 | US$1.2t | US$203.5b | US$1.7b | 14.1x | 695.4x | 5.7x |
| Fri, 09 Dec 2022 | US$1.2t | US$202.7b | US$1.4b | 14.9x | 819.9x | 5.8x |
| Sun, 06 Nov 2022 | US$1.1t | US$204.6b | US$3.6b | 14.2x | 299.5x | 5.3x |
| Tue, 04 Oct 2022 | US$1.0t | US$206.2b | US$5.5b | 14.6x | 189.3x | 5x |
| Thu, 01 Sep 2022 | US$1.0t | US$206.4b | US$7.3b | 14.1x | 140x | 5x |
| Sat, 30 Jul 2022 | US$1.1t | US$212.0b | US$11.3b | 15.6x | 93.2x | 5x |
| Mon, 27 Jun 2022 | US$1.1t | US$212.4b | US$11.1b | 15.4x | 95.1x | 4.9x |
| Wed, 25 May 2022 | US$992.4b | US$212.8b | US$11.1b | 15.7x | 89.2x | 4.7x |
Price to Earnings Ratio
89.2x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.9% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 5.34% | |
| Healthcare | 0.68% | |
| Biotech | 3.71% | |
| Biotech | 3.71% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | US$594.32 | 12.6% +US$7.0b | -39.5% | PE14x | |
| GILD Gilead Sciences | US$102.50 | 5.8% +US$7.0b | 51.4% | PE21.4x | |
| ALNY Alnylam Pharmaceuticals | US$285.31 | 13.6% +US$4.5b | 91.0% | PS15.8x | |
| AMGN Amgen | US$272.41 | 2.5% +US$3.5b | -12.8% | PE24.7x | |
| VRTX Vertex Pharmaceuticals | US$438.65 | 3.2% +US$3.5b | -1.5% | PS10.1x |
